Selicrelumab

DB14958Investigational

Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Also known as: CP 870,893

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Selicrelumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.